Olinciguat
As of the edition of 20 October 2026, Olinciguat is a small molecule: went quiet in 2020; acts on GUCY1A1, GUCY1A2 and GUCY1B1 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Small molecule
- Registered trials
- 6, 1 stopped early
- Disease areas
- Blood and lymph; Digestive system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cyclerion Therapeutics | Lead sponsor of trials | 2015 to now |